Clinical impact of a personalized pharmaceutical plan on opioid management in non-cancer pain: a pilot study.
Clinical pharmacy
Opioids
Pain management
Pharmaceutical care
Pharmaceutical interview
Rheumatic disease
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
01
05
2021
accepted:
11
05
2021
revised:
01
05
2021
pubmed:
26
5
2021
medline:
21
10
2021
entrez:
25
5
2021
Statut:
ppublish
Résumé
Non-cancer pain of the locomotor apparatus is the main symptom justifying referral to a rheumatologist with potential introduction of opioids, leading to addiction if misused. The objective was to evaluate the impact of a personalized pharmaceutical plan on patients' knowledge of their opioid treatment and its duration. This prospective non-randomized pilot study was conducted during 7 months with standardized data collected in a French rheumatology department. Patients with rheumatic diseases and non-cancer pain requiring opioid treatment were included. The intervention group had a 30-min opioid-targeted pharmaceutical interview and received a full medication plan and the control group received usual care. A total of 17 patients were included in the intervention group and 18 in the control group. Among patients in the intervention group, only 6 (35%) knew that immediate-release opioids have a rapid and short action, 9 (53%) were worried about taking opioids, and 13 (76%) reported that they would refer to the information document provided if side effects occurred. A trend toward a shorter duration of treatment was observed in the study group (HR = 1.87, 95% CI 0.93 to 3.76, p = 0.08), but this trend was attenuated when adjusting on hospital duration (HR = 1.53, 95% CI 0.74 to 3.15, p = 0.25). This pilot study provides preliminary evidence on the role of the clinical pharmacist in the management of non-cancer pain with strong opioids. Clinical benefits will be assessed in a randomized study. Key Points • Knowledge of opioids is insufficient in rheumatology patients with non-cancer pain. • Pharmaceutical interviews may improve patients' knowledge of opioids.
Identifiants
pubmed: 34032934
doi: 10.1007/s10067-021-05776-7
pii: 10.1007/s10067-021-05776-7
doi:
Substances chimiques
Analgesics, Opioid
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
4659-4663Informations de copyright
© 2021. International League of Associations for Rheumatology (ILAR).
Références
Deyo RA, Von Korff M, Duhrkoop D (2015) Opioids for low back pain. BMJ 350:g6380. https://doi.org/10.1136/bmj.g6380
doi: 10.1136/bmj.g6380
pubmed: 25561513
pmcid: 6882374
Warner EA (2012) Opioids for the treatment of chronic noncancer pain. Am J Med 125(12):1155–1161. https://doi.org/10.1016/j.amjmed.2012.04.032
doi: 10.1016/j.amjmed.2012.04.032
pubmed: 22944349
Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN (2015) Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 156(4):569–576. https://doi.org/10.1097/01.j.pain.0000460357.01998.f1
doi: 10.1097/01.j.pain.0000460357.01998.f1
pubmed: 25785523
Leguelinel-Blache G, Dubois F, Bouvet S et al (2015) Improving patient’s primary medication adherence: the value of pharmaceutical counseling. Medicine (Baltimore) 94(41):e1805. https://doi.org/10.1097/md.0000000000001805
doi: 10.1097/md.0000000000001805
Genord C, Frost T, Eid D (2017) Opioid exit plan: a pharmacist’s role in managing acute postoperative pain. J Am Pharm Assoc (2003) 57(2s):S92-s8. https://doi.org/10.1016/j.japh.2017.01.016
doi: 10.1016/j.japh.2017.01.016
Soubieux A, Chenailler C, Lattard C, Banse C, Kozyreff-Meurice M, Gondé H et al (2020) The impact of an in-department pharmacist on the prevention of drug iatrogenesis in a rheumatology department. Clin Rheumatol. https://doi.org/10.1007/s10067-020-05138-9
doi: 10.1007/s10067-020-05138-9
pubmed: 32519050
Al-Masri D, Wilbur K, Elazzazy S, Hassan AA, Wilby KJ (2020) Law, culture, and fear: a qualitative study of health professionals’ perceptions of narcotic use related to cancer pain. J Pain Palliat Care Pharmacother 34(1):1–8. https://doi.org/10.1080/15360288.2019.1704340
doi: 10.1080/15360288.2019.1704340
Clifford S, Barber N, Elliott R, Hartley E, Horne R (2006) Patient-centred advice is effective in improving adherence to medicines. Pharm World Sci 28(3):165–170. https://doi.org/10.1007/s11096-006-9026-6
doi: 10.1007/s11096-006-9026-6
pubmed: 17004019
Chisholm-Burns MA, Spivey CA, Sherwin E, Wheeler J, Hohmeier K (2019) The opioid crisis: origins, trends, policies, and the roles of pharmacists. Am J Health Syst Pharm 76(7):424–435. https://doi.org/10.1093/ajhp/zxy089
doi: 10.1093/ajhp/zxy089
pubmed: 31361827
Poirier RH, Brown CS, Baggenstos YT et al (2019) Impact of a pharmacist-directed pain management service on inpatient opioid use, pain control, and patient safety. Am J Health Syst Pharm 76(1):17–25. https://doi.org/10.1093/ajhp/zxy003
doi: 10.1093/ajhp/zxy003
pubmed: 31381097
Boren LL, Locke AM, Friedman AS, Blackmore CC, Woolf R (2019) Team-based medicine: incorporating a clinical pharmacist into pain and opioid practice management. PM&R 11(11):1170–1177. https://doi.org/10.1002/pmrj.12127
doi: 10.1002/pmrj.12127